SCHEMBL25301241

SCHEMBL25301241

Fc1ccccc1[CH]C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 10/20 0.56
GRIN2D O15399 2/20 0.41
GRIN3B O60391 2/20 0.41
GRIN1 Q05586 2/20 0.41
GRIN2A Q12879 2/20 0.41
GRIN2B Q13224 2/20 0.41
GRIN2C Q14957 2/20 0.41
GRIN3A Q8TCU5 2/20 0.41
IKBKB O14920 2/20 0.38
LMNA P02545 1/20 0.38
RAF1 P04049 1/20 0.38
RPS6KB1 P23443 1/20 0.38
MAPK1 P28482 1/20 0.38
AKT1 P31749 1/20 0.38
AKT2 P31751 1/20 0.38
KDR P35968 1/20 0.38
PRKAG1 P54619 1/20 0.38
MAP2K1 Q02750 1/20 0.38
PRKAA1 Q13131 1/20 0.38
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208739 0.74
SCHEMBL16225857 0.73 NFKB1 (0.52) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15557143 0.73 HSD11B1 (0.42) NFE2L2IKBKBMAPK1DYRK2
SCHEMBL8057386 0.73 ALDH1A1 (0.50) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2118262 0.73 NFE2L2 (0.68) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2234105 0.73 NFE2L2 (1.00) NFE2L2
SCHEMBL1381636 0.71 NFE2L2 (0.50) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL575116 0.70
SCHEMBL3247717 0.70 RXRA (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15353049 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11999717-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-06-04 US disclosed
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999717-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof LPAR3, LPAR1, LPAR2 NFE2L2 4702/4885GRIN2D 4484/4885GRIN3B 3477/4885
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR3, LPAR1, LPAR2 NFE2L2 4702/4885GRIN2D 4484/4885GRIN3B 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.